Search Results - "BRCA mutation"

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds by Rita De Sanctis, Rita De Sanctis, Flavia Jacobs, Flavia Jacobs, Chiara Benvenuti, Chiara Benvenuti, Mariangela Gaudio, Mariangela Gaudio, Raul Franceschini, Richard Tancredi, Paolo Pedrazzoli, Paolo Pedrazzoli, Armando Santoro, Armando Santoro, Alberto Zambelli, Alberto Zambelli

Connect to this object online.

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond by Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis

Connect to this object online.

Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review by Shona Nag, Shyam Aggarwal, Amit Rauthan, Narayanankutty Warrier

Connect to this object online.

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer by Anna Jo Bodurtha Smith, Annie Apple, Audra Hugo, Ashley Haggerty, Emily M. Ko

Connect to this object online.

Concomitant diagnosis of endometrial and breast cancer - does the sequence matters? by Tomer Stern, Shira Peleg Hasson, Akram Saad, Keren Levanon, Nadav Michaan, Ido Laskov, Ido Wolf, Dan Grisaru, Tamar Safra

Connect to this object online.

Knowledge and Anxiety Related to Hereditary Ovarian Cancer in Serous Ovarian Cancer Patients by Sang Hee Lee, Hyangkyu Lee, Myong Cheol Lim, Sue Kim

Connect to this object online.

Screening of high-risk groups for breast and ovarian cancer in Europe: a focus on the Jewish population by Karen L. Belkic, Miri Cohen, Marcela Marquez, Miriam Mints, Brigitte Wilczek, Anne H. Berman, Enrique Castellanos, Martha Castellanos

Connect to this object online.

BRCA1 c.68_69delAG (exon2), c.181T>G (exon5), c.798_799delTT and 943ins10 (exon11) mutations in Burkina Faso by Abdou Azaque Zoure, Meriem Slaoui, Hierrhum Aboubacar Bambara, Alexis Yobi Sawadogo, Tegwendé Rebeca Compaoré, Nabonswindé Lamoussa Marie Ouédraogo, Mohammed El Mzibri, Mohammed Attaleb, Si Simon Traoré, Jacques Simpore, Youssef Bakri

Connect to this object online.

Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis by Nicholas Adrianto, Ghea Mangkuliguna, Eunike Jennifer Tandiono, Candra Novi Ricardo Sibarani

Connect to this object online.

Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know? by Boccia SM, Sassu CM, Ergasti R, Vertechy L, Apostol AI, Palluzzi E, Fagotti A, Scambia G, Marchetti C

Connect to this object online.

DNA damage targeted therapy for advanced breast cancer by Vanessa Patel, Sandra Casimiro, Catarina Abreu, Tiago Barroso, Rita Teixeira de Sousa, Sofia Torres, Leonor Abreu Ribeiro, Gonçalo Nogueira-Costa, Helena Luna Pais, Conceição Pinto, Leila Costa, Luís Costa

Connect to this object online.

Genetic Testing Among Breast Cancer Patients in the Eastern Region of Saudi Arabia: Single-Center Experience by Ghadeer Al Ghareeb, Zainab Al Nass, Salma Abu-Grain, Alia Alnaji, Hani Almohanna, Hadi Al Shaikh Nasser, Saad Al Shahrani

Connect to this object online.

¿SE JUSTIFICA LA OOFORECTOMÍA, COMO MEDIDA PROFILÁCTICA EN LA DISMINUCIÓN DEL RIESGO DE CÁNCER DE OVARIO Y DE MAMA, EN LAS PACIENTES PORTADORAS DE MUTACIONES EN LOS GENES BRCA1... by Marcelo González V, Demetrio Larraín de la C, Maximiliano Figueroa M

Connect to this object online.

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma by Zheng Feng, Di Shao, Yuhang Cai, Rui Bi, Xingzhu Ju, Dongju Chen, Chengcheng Song, Xiaojun Chen, Jin Li, Na An, Yunjin Li, Qing Zhou, Zhihui Xiu, Shida Zhu, Xiaohua Wu, Hao Wen

Connect to this object online.

Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature by Daniela Luvero, Roberto Angioli, Federica Celoro, Francesco Plotti, Corrado Terranova, Federica Guzzo, Gianna Barbara Cundari, Federico Liparulo, Camilla Verdone, Roberto Montera

Connect to this object online.

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer by D.  A. Morozov, I. V. Kolyadina, I. V. Poddubnaya, I.  P. Ganshina, S. V. Khokhlova, V. V. Kometova, V. V. Rodionov

Connect to this object online.

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies by Attwa MW, Kadi AA, Abdelhameed AS, Alhazmi HA

Connect to this object online.

Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation by Barbora Orlikova-Boyer, Anne Lorant, Sruthi Reddy Gajulapalli, Claudia Cerella, Michael Schnekenburger, Jin-Young Lee, Ji Yeon Paik, Yejin Lee, David Siegel, David Ross, Byung Woo Han, Thi Kim Yen Nguyen, Christo Christov, Hyoung Jin Kang, Mario Dicato, Marc Diederich

Connect to this object online.